The Fight Against Fentanyl: Kloxxado® and Hikma in the News

Even though Kloxxado^® (naloxone HCl) nasal spray 8 mg received FDA approval more than two years ago, it continues to get plenty of press. Kloxxado^®, which contains twice as much naloxone per spray as Narcan^® (naloxone HCl) Nasal Spray 4 mg,^1,2 represents an important tool in the fight against the opioid overdose epidemic. Read about Kloxxado^® in the news, including these updates from the past year.

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility³

Hikma Pharmaceuticals PLC welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP) to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma’s and the ONDCP’s shared goal of expanding availability and awareness of life-saving naloxone. During the visit, Dr. Gupta toured the manufacturing facility, observing the production of Hikma’s overdose reversal medicine, Kloxxado^® (naloxone HCl) nasal spray 8 mg, and participated in a roundtable discussion with Hikma leadership as well as representatives from two Ohio-based harm reduction organizations. Topics of discussion included the ongoing opioid epidemic and how industry, government, community organizations and others can work together to meet the urgent needs of US patients and communities.

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House meeting⁴

This past June, Hikma Pharmaceuticals reaffirmed its commitment to expanding access to naloxone while participating with the Office of National Drug Control Policy (ONDCP) in a White House conversation on opioid reversal agents. Through its Hikma Community Health Initiative, the company is partnering with other organizations on the frontlines of the opioid overdose crisis to help expand access to naloxone nationwide. Hikma has donated more than 450,000 doses of Kloxxado^® and injectable naloxone to harm reduction groups, community organizations and others across the US. Dr. Hafrun Fridriksdottir, President of Hikma’s Generics business, said, “We are partnering with health care providers, non-profit organizations and the public health community to ensure naloxone is widely accessible to all who can benefit from it.”

Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House meeting | Hikma

Hikma’s Kloxxado^® Naloxone Nasal Spray shelf-life extended⁵

With the increasing prevalence of illicitly manufactured synthetic opioids, organizations including the CDC, the AMA and others have noted that a higher dose of naloxone may be required to revive a patient experiencing poisoning from Illicit fentanyl or other opioids. (Kloxxado^®, manufactured by Hikma Pharmaceuticals USA Inc., contains twice as much naloxone per spray as Narcan^® to reverse the effects of opioid overdose.) Hikma recently announced the shelf-life extension of ready-to-use Kloxxado^® nasal spray from 24 to 36 months, starting with product manufactured in 2024. “Good news for frontline responders and the thousands of people who carry Kloxxado^® and who may need to use it at a moment’s notice to reverse an overdose,” said Hafrun Fridricksdottir, president of Hikma generics.

Hikma’s Kloxxado Naloxone Nasal Spray shelf-life extended | Drug Store News

Representative Buddy Carter visits Groves High School for Naloxone training event⁶

This past August, Georgia state representative Earl L. “Buddy” Carter hosted a naloxone training event at Groves High School in Georgia’s First Congressional District. Attended by businesses and citizens alike, Rep Carter detailed the importance of carrying naloxone and how it can be used to reverse the effects of opioid overdoses, even those involving fentanyl. In an interview with WTOC Channel 11, Carter said, “If you can reverse those effects, even temporarily, it can save lives.”

Representative Buddy Carter visits Groves High School for Naloxone training event

Times Square Event Marks National Fentanyl Prevention Day⁷

Andrea Thomas founded the nonprofit Facing Fentanyl after the tragic loss of her daughter, Ashley Romero, to accidental fentanyl poisoning. The organization took over Times Square on August 21 to mark the third annual National Fentanyl Prevention and Awareness Day. A highlight of the event was the unveiling of a Facing Fentanyl billboard, which lit up Times Square for 20 minutes and featured images of people lost to fentanyl. In addition to this tribute, Facing Fentanyl members distributed naloxone at the event, talked with passersby and answered questions. Also in attendance were James Carroll, former Director of the White House ONDCP; Michael Fiore, a recovery advocate; Jaime Puerta, head of Victims of Illicit Drugs (VOID) and Frank Tarentino, the Special Agent in charge of the Drug Enforcement Administration’s New York Division.

Times Square Event Marks National Fentanyl Prevention Day | Midtown, NY Patch

Couple Gives Out Opiate Reversal Spray At Sea.Hear.Now. Music Fest⁸

In September, thousands of music fans came to Asbury Park, New Jersey to attend the Sea.Hear.Now. music festival. Highlights included a homecoming performance from Bruce Springsteen and the E Street Band, as well as many other well-known musical acts. Among the crowds were husband-and-wife team William Perry and Ingela Travers-Hayward from the Ohio-based non-profit, This Must Be the Place. The pair travels to concerts and music festivals across the US, giving out opioid overdose reversal drugs like Kloxxado^® (naloxone HCl) nasal spray 8 mg and educating attendees about the dangers of fentanyl. A similar group called End Overdose distributes Kloxxado^® at events that include Insomniac Music Festivals and raves across the country.

Couple Gives Out Opiate Reversal Spray At Sea.Hear.Now This Weekend | Asbury Park, NJ Patch

Kloxxado^® is a registered trademark of Hikma Pharmaceutals USA Inc.

All other registered trademarks are the property of their respective owners.

Please see the Full Prescribing Information and Medication Guide for Kloxxado^® for complete product details.

NOTE: This article was not written by a medical professional and is not intended to substitute for the guidance of a physician. These are not Hikma’s recommendations, but rather facts and data collected from various reliable medical sources. For a full list of resources and their attributing links, see below.

HK-3186v1